• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用凝血酶原复合物浓缩剂治疗患有凝血因子 VIII 抑制剂的儿童的长期结果。

Long-term results of the treatment of children with factor VIII inhibitors with prothrombin-complex concentrates.

作者信息

Ekert H, Smibert E, Exton J

机构信息

Department of Clinical Haematology, Royal Children's Hospital, Parkville, Vic.

出版信息

Med J Aust. 1987 Sep 7;147(5):230-3. doi: 10.5694/j.1326-5377.1987.tb133415.x.

DOI:10.5694/j.1326-5377.1987.tb133415.x
PMID:3118153
Abstract

Twelve boys with haemophilia and factor VIII inhibitors have received initial treatment for each episode of bleeding with prothrombin-complex concentrate. The follow-up period for these boys has ranged from two months to 14 years, and a total of 732 bleeding episodes were reviewed. Each boy underwent a full clinical and radiological assessment of knee-joint function, and this was compared with knee-joint function in 29 patients with severe haemophilia but without factor VIII antibodies. A change of treatment from prothrombin-complex concentrate to some other form of therapy was considered to be required in only 4% of the bleeding episodes. Of 10 severe bleeding episodes, five episodes clearly were controlled with prothrombin-complex concentrate, but five episodes necessitated alternative treatment. Four of the 12 families considered prothrombin-complex concentrate as relatively ineffective. All boys who were older than 10 years of age showed grade-1 or grade-2 impairment of knee-joint mobility, as well as radiological evidence of moderate-to-severe knee-joint changes. In the group of haemophiliac patients who were older than 10 years of age and did not have factor VIII antibodies, only 10 of the 58 knee-joints that were examined showed grade-1 or grade-2 functional impairment. Although prothrombin-complex concentrates were effective in the control of the majority of minor bleeding episodes, they were effective in only 50% of severe episodes of bleeding and did not prevent the early development of haemophilic arthropathy.

摘要

12名患有血友病且体内有因子VIII抑制物的男孩,每次出血发作时均接受了凝血酶原复合物浓缩剂的初始治疗。这些男孩的随访期为2个月至14年,对总共732次出血发作进行了回顾。对每个男孩的膝关节功能进行了全面的临床和放射学评估,并与29名患有严重血友病但无因子VIII抗体的患者的膝关节功能进行了比较。仅4%的出血发作被认为需要从凝血酶原复合物浓缩剂改为其他某种治疗形式。在10次严重出血发作中,5次明显通过凝血酶原复合物浓缩剂得到了控制,但5次需要替代治疗。12个家庭中有4个认为凝血酶原复合物浓缩剂相对无效。所有年龄超过10岁的男孩均表现出1级或2级膝关节活动障碍,以及中度至重度膝关节改变的放射学证据。在年龄超过10岁且无因子VIII抗体的血友病患者组中,所检查的58个膝关节中只有10个表现出1级或2级功能障碍。尽管凝血酶原复合物浓缩剂在控制大多数轻度出血发作方面有效,但在仅50%的严重出血发作中有效,且不能预防血友病性关节病的早期发展。

相似文献

1
Long-term results of the treatment of children with factor VIII inhibitors with prothrombin-complex concentrates.使用凝血酶原复合物浓缩剂治疗患有凝血因子 VIII 抑制剂的儿童的长期结果。
Med J Aust. 1987 Sep 7;147(5):230-3. doi: 10.5694/j.1326-5377.1987.tb133415.x.
2
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.活化凝血酶原复合物浓缩剂(FEIBA)对甲型血友病及抗凝血因子 VIII 抗体患者关节和肌肉出血的影响。一项双盲临床试验。
N Engl J Med. 1981 Sep 24;305(13):717-21. doi: 10.1056/NEJM198109243051301.
3
Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.凝血酶原复合物浓缩剂在伴有抗凝血因子VIII抗体的血友病患者中的疗效:一项多中心治疗试验。
N Engl J Med. 1980 Aug 21;303(8):421-5. doi: 10.1056/NEJM198008213030803.
4
Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.长期使用活化凝血酶原复合物浓缩剂进行预防并不能阻止现有关节疾病的进展。
Haemophilia. 2003 May;9(3):261-8. doi: 10.1046/j.1365-2516.2003.00771.x.
5
Articular Bleeding in Hemophilia.血友病中的关节出血
Cardiovasc Hematol Disord Drug Targets. 2016;16(1):21-24. doi: 10.2174/1871529x16666160613114506.
6
The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.非活化凝血酶原复合物浓缩物在伴有Ⅷ因子抗体的甲型血友病治疗中的应用。
Aust N Z J Med. 1977 Jun;7(3):286-90. doi: 10.1111/j.1445-5994.1977.tb03688.x.
7
A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII.一项针对患有血友病且体内存在抗凝血因子 VIII 抗体的儿童进行的凝血因子 VIII 或凝血酶原复合物浓缩剂输注的随机研究。
Aust N Z J Med. 1979 Jun;9(3):241-4. doi: 10.1111/j.1445-5994.1979.tb04130.x.
8
Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.使用活化凝血酶原复合物浓缩剂(FEIBA)进行预防性治疗可降低患有血友病A且产生抑制剂的儿科患者出血事件的发生频率。
Haemophilia. 2007 May;13(3):249-55. doi: 10.1111/j.1365-2516.2007.01442.x.
9
Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
JAMA. 1976 Nov 1;236(18):2061-4. doi: 10.1001/jama.236.18.2061.
10
Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor.
Am J Pediatr Hematol Oncol. 1993 Nov;15(4):416-9.